Xtant grants COO 450K deferred stock units

Xtant Medical Holdings, Inc. (XTNT) reported equity compensation changes for Chief Operating Officer Mark A. Schallenberger.

Rhea-AI Filing Summary

Xtant Medical Holdings, Inc. (XTNT) reported equity compensation changes for Chief Operating Officer Mark A. Schallenberger. He received a grant of 450,000 deferred stock units (DSUs), which will vest in four equal installments of 112,500 shares on August 15 of each year from 2027 through 2030, conditioned on continued employment. Settlement of the vested DSUs into common stock will occur at a later date under the award terms. Separately, 7,070 shares of common stock were withheld at $0.31 per share to satisfy tax withholding obligations upon vesting and settlement of restricted stock units.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Schallenberger Mark A.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	450,000	$0.00	$0.00
Tax Withholding	Common Stock F3, F2	7,070	$0.31	$2K

Holdings After Transaction: Common Stock — 1,106,087 shares (Direct)

Footnotes (3)

1. F1. These shares will vest with respect to 112,500 shares on each of August 15, 2027, August 15, 2028, August 15, 2029, and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Includes an aggregate of 944,758 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.
3. F3. These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

Key Figures

DSU grant: 450,000 shares Annual DSU vesting tranche: 112,500 shares Tax withholding shares: 7,070 shares +3 more

6 metrics

DSU grant 450,000 shares Deferred stock unit award granted to COO on August 15, 2026

Annual DSU vesting tranche 112,500 shares Portion of DSU grant vesting each August 15 from 2027 to 2030

Tax withholding shares 7,070 shares Shares withheld to satisfy tax obligations upon RSU vesting

Tax withholding price $0.31 per share Per-share value used for shares withheld for tax obligations

Unvested RSU/DSU under 2023 plan 944,758 shares Shares issuable upon vesting and settlement of RSU or DSU awards

Unvested RSU under 2018 plan 22,250 shares Shares issuable upon vesting and settlement of RSU awards

Key Terms

deferred stock unit (DSU), restricted stock unit (RSU), Amended and Restated 2023 Equity Incentive Plan, tax withholding obligations

4 terms

deferred stock unit (DSU) financial

"pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical"

restricted stock unit (RSU) financial

"settlement of restricted stock unit (RSU) awards granted under the Xtant Medical"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Amended and Restated 2023 Equity Incentive Plan financial

"under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan"

tax withholding obligations financial

"shares were withheld by the Issuer to pay tax withholding obligations upon vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did XTNT grant to COO Mark Schallenberger on August 15, 2026?

XTNT granted Mark Schallenberger 450,000 deferred stock units (DSUs) on August 15, 2026. These DSUs vest in four equal tranches of 112,500 shares each year from 2027 to 2030, contingent on his continued employment with the company.

How do the new XTNT DSUs for Mark Schallenberger vest over time?

The 450,000 XTNT DSUs vest in four equal installments of 112,500 shares on August 15, 2027, 2028, 2029, and 2030. Vesting is conditioned on Schallenberger remaining an employee through each applicable vesting date.

When will the XTNT DSUs granted to Mark Schallenberger be settled into common stock?

Settlement of the vested XTNT DSUs will occur at a later date according to the DSU award agreement. Each DSU represents a contingent right to receive one share of Xtant Medical’s common stock when settled.

Why did XTNT withhold 7,070 shares from Mark Schallenberger?

XTNT withheld 7,070 shares of common stock at $0.31 per share to pay tax withholding obligations. This withholding occurred upon the vesting and settlement of restricted stock unit awards previously granted to Mark Schallenberger.

How many XTNT shares are tied to Schallenberger’s unvested RSU and DSU awards?

Schallenberger has an aggregate of 944,758 shares issuable upon vesting and settlement of RSU or DSU awards under the 2023 plan, plus 22,250 shares issuable under the 2018 plan, all contingent on continued employment through applicable vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 06:03 PM Accepted by SEC EDGAR 08/18/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schallenberger Mark A.

(Last) (First) (Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE MONTANA 59714

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2026		A		450,000(1)	A	$0	1,113,157(2)	D
Common Stock	08/15/2026		F(3)		7,070(3)	D	$0.31	1,106,087(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares will vest with respect to 112,500 shares on each of August 15, 2027, August 15, 2028, August 15, 2029, and August 15, 2030 pursuant to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes an aggregate of 944,758 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

3. These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

	/s/ Amy Culbert, attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)